HUmani

Charleroi 19 trials 11 recruiting

19 Registered trials

11 Currently recruiting

Organisation

HUmani

Location

Charleroi, Belgium

Identifier

ORG-100042341

Address

Rue De Gozee 706, 6110, Belgium

Departments

Cardiology
Intensive Care
Intensive Care Unit
Neonatologie
Néphrologie
Nephrology
Neurology department – C.H.U. de Charleroi Site Hôpital Civil Marie Curie (HCMC)
oncologie
Oncology
Pédiatrie
Pneumology

Clinical trials at this site (19)

Search interface

HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Not authorised

2024-516253-49-00 advanced/metastatic HER2-positive breast carcinoma 4
A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have compl… Pending

2024-519638-22-00 IgA nephropathy 5
HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Recruiting

2024-516253-49-01 advanced/metastatic HER2-positive breast carcinoma 4 2025-12-12
Safety and effect of mesenchymal derived Extracellular Vesicles in the prevention of Bronchopulmonary Dysplasia in extremely preterm newborn… Recruiting

2022-500293-34-01 Bronchopulmonary Dysplasia 7 2023-12-28
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A randomized, double-blind, placebo-controlled, multicentre trial, assessing the impact of ferric carboxymaltose on exercise capacity and fu… Recruiting

2025-522936-14-00 Pulmonary hypertension 6 2026-01-27
A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIR… Recruiting

2023-510109-16-00 Acute Respiratory Distress Syndrome (ARDS) Due to Pneum 4 2025-01-06
Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc… Recruiting

2023-506703-26-00 locally advanced rectal cancer 5 2024-02-07
COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention Recruiting

2023-505028-74-00 Coronary artery disease 5 2024-01-29
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting

2022-502851-79-00 Active Idiopathic Inflammatory Myopathy (IIM) 5 2023-09-20
WOEST-3 Recruiting

2022-502140-13-00 Atrial fibrillation Acute coronary syndrome Chronic cor 6 2023-01-11
A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended

2024-518457-42-00 chronic kidney disease 4 2025-08-28
Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended

2022-502238-22-00 Ulcerative Colitis 5 2024-05-14
A study to test trimodulin in adult hospitalized patients with severe pneumonia Ended

2022-501352-28-00 Severe community-acquired pneumonia (sCAP) 5 2023-06-07
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
Effect of NAL in participants with sleep disorders Ended

2023-508445-40-00 Obstructive Sleep Apnea 4 2024-07-01
A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon… Ended

2023-506981-30-00 Chronic kidney disease in type 2 diabetes mellitus 4 2022-05-25
Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-… Ended

2024-516783-29-00 Severe allergic and eosinophilic asthma 6 2018-04-16